Review of frovatriptan in the treatment of migraine by Kelman, Leslie
© 2008 Dove Medical Press Limited.   All rights reserved
Neuropsychiatric Disease and Treatment 2008:4(1) 49–54 49
EXPERT OPINION
Review of frovatriptan in the treatment of migraine
Leslie Kelman
Headache Center of Atlanta, Atlanta, 
GA, USA
Correspondence: Leslie Kelman
Headache Center of Atlanta, 5671 
Peachtree Dunwoody Road, Suite 620
Atlanta, GA 30342, USA
Tel +1 404 843 9958
Fax +1 404 843 1883
Email lkelman@mindspring.com
Abstract: Triptans are recommended for the acute treatment of moderate to severe migraine 
or failure to respond to other acute migraine treatments. Seven triptans are available providing 
a wide range of choices. These triptans are more similar than dissimilar but patients do note 
differences in effectiveness and in tolerance. Also migraine situations may differ from attack to 
attack, providing the opportunity to exploit the uniqueness of a particular triptan. Frovatriptan 
has a uniquely long-half life, ﬁ  ve times that of other triptans. This provides the opportunity to 
use frovatriptan in mini-prophylaxis such as in menstrual-related migraine and other situations, 
as well as use in long-lasting or recurrent migraine.
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Introduction
Migraine is a common disorder, occurring in 17% of women and 6% of men in the 
United States (Lipton et al 2007). Migraine disability is pervasive, for the individual, 
the family, and the work place (Santanello et al 2002). This is magniﬁ  ed by the high-
est prevalence occurring in the most productive and most reproductive years of life 
(Leonardi et al 2005). Since the initial discovery of compound GR43175 (sumatriptan) 
(Humphrey et al 1988), and its ﬁ  rst tentative therapeutic publication (Doenicke et al 
1988) this class of drugs, the triptans, has revolutionized the management and the 
lives of migraineurs. Seven different triptans are now available, some with different 
formulations (Lipton 1998; Silberstein 2000; Ferrari et al 2002; Rapoport et al 2003; 
Lucas 2006). Prescribers and consumers are seeking the “best” triptan to use. The ﬁ  rst 
decision is usually based on the formulation. It is generally acknowledged that if: the 
headache is advanced (waking from sleep with, or due to, the migraine attack); there 
is early nausea or vomiting; there is rapid escalation of the migraine attack (migraine 
pain or associated symptoms reaching peak early in the migraine attack); or there is an 
urgent time line (such as pending business trip or meeting, car pooling) a formulation 
that reaches the brain early may required. In these situations sumatriptan subcutaneous 
injection or intranasal sumatriptan or zolmitriptan may by the optimum treatment. All 
seven triptans have oral preparations. The pharmacological actions are more similar than 
dissimilar. However, migraineurs frequently report differences in triptan effectiveness 
and adverse effects. Most of the oral triptans have similar pharmacologic properties. 
This review focuses on frovatriptan which has some unique pharmacological proper-
ties affording some distinct potential clinical uses.
Migraine pathophysiology and the triptans
During the past decade there has been a rapid increase in our understanding of the 
pathophysiology of migraine. To some extent this has been driven by attempts to better 
understand the mechanism of action of the triptans.
Paramount in the migraineur may be the genetic makeup. This is strongly suggested 
in the clinic by the high percentage of patients reporting migraine in ﬁ  rst degree rela-
tives (Silberstein et al 2002). A large twin epidemiological study showed a signiﬁ  cantly Neuropsychiatric Disease and Treatment 2008:4(1) 50
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higher concordance rate for migraine in monozygotic twins 
compared to dizygotic twins (p   0.05) (Ulrich et al 1999). In 
50% of families with familial hemiplegic migraine the disor-
der has been linked to chromosome 19p13 (Joutel et al 1994; 
Russell et al 1995). Other mutations have been documented 
in a smaller percentage of patients. However, no consistent 
genetic makeup has been deﬁ  ned in most migraine patients.
The peripheral component of the migraine process is 
vested in the surface vessels with surrounding trigeminal 
ﬁ  bers, linking to the trigeminal ganglion. The trigeminal 
ganglion and most sensory nerves are rich in substance P (SP) 
and calcitonin gene related peptide (CGRP) (Uddman et al 
1985). These neurotransmitters are released with activation of 
the trigeminal ganglion (Goadsby et al 1988) and their release 
may be initiated by cortical spreading depression (Mos-
kowitz et al 1993; Ingvardsen et al 1997a, b; Ebersberger 
et al 2001; Goadsby 2001; Bolay et al 2002). The resulting 
leakage of plasma from dural blood is known as neurogenic 
plasma extravasation (Markowitz et al 1987) and this sterile 
inﬂ  ammation may be responsible for the pain of migraine 
(Moskowitz 1990). Input from the C2 root is also part of the 
peripheral system (Goadsby et al 1997a).
The central component of the migraine process encompasses 
the trigeminal nucleus caudalis and its rostral connections. 
Stimulation of either the trigeminal system or C2 results in 
measurable activity in the trigeminal nucleus caudalis (Nozaki 
et al 1992; Kaube et al 1993; Goadsby and Hoskin 1997; 
Goadsby et al 1997b; Hoskin et al 1999). Information is then 
relayed to the thalamus; this has been demonstrated in human 
imaging studies where activation of the thalamus contralateral 
to the pain has been shown (Weiller et al 1995a).
Exerting a level of control over the above system is the 
central modulation of pain. PET functional scanning during 
treatment of migraine without aura (episodic or chronic) 
has shown activation of the periaqueductal grey matter 
(PAG), dorsal pons, and the locus coeruleus (Weiller et al 
1995b; Bahra et al 2001; Matharu et al 2004; Afridi et al 
2005). Stimulation of the PAG inhibits sagittal sinus-evoked 
trigeminal neuronal activity (Knight and Goadsby 2001), 
while blocking P/Q-type voltage-gated calcium channels in 
the PAG facilitates trigeminovascular nociceptive processing 
(Knight et al 2002).
“Migraine is probably caused by a combination of dys-
modulation and afferent sensory activation.” (Goadsby 2005). 
Thus, the migraine attack occurs in the genetically susceptible 
individual. This may be triggered by internal or external 
events, possibly as a result of spreading cortical depression. 
Subsequent activation of the peripheral mechanisms causes 
peripheral sensitization to occur leading to activation of the 
central mechanisms. This in turn may be affected by central 
modulation. It appears that once the central sensitization has 
occurred, the process may be less be amenable to the action 
of triptans (Burstein et al 2004).
Where then do the triptans exert their action? 1) They 
cause selective extracerebral intracranial vasoconstriction. 2) 
They inhibit trigeminal nerve terminals innervating extrace-
rebral vessels. 3) They potentially produce central neuronal 
inhibition in the nucleus caudalis (Humphrey 2007).
Frovatriptan pharmacology
Cerebral vasodilatation and neurogenic inflammation are 
considered to be prime movers in the pathogenesis of migraine 
(Moskowitz 2003). Activation of 5-HT1B reverses cerebral 
vasodilatation and activation of 5-HT1D prevents neurogenic 
inﬂ  ammation (Moskowitz 1992; Goadsby and Olesen; 1996 
Longmore et al 1997). Frovatriptan like other triptans has a 
high afﬁ  nity for 5-HT1B and 5-HT1D receptors and a moderate 
affinity for the 5-HT1A and 5-HT1F receptors subtypes. 
Frovatriptan has been shown to be one of the most potent 5-
HT1B agonists (Brown et al 1998; Stewart et al 1999). Unlike 
most other triptans, frovatriptan has a moderate afﬁ  nity for the 
5-HT7 receptors (Brown et al 1996), an action associated with 
coronary artery relaxation in the dog (Cushing et al 1996).
Frovatriptan pharmacokinetics 
(Buchan 1998; Buchan et al 1998, 
1999; Cohen et al 1999)
Oral bioavailability of frovatriptan is 22%– 30% and is not 
affected by food. Although the maximum concentration in the 
plasma is achieved in 2–3 hours, 60%–70% of this is achieved 
in 1 hour. A steady state is achieved in 4–5 days. Plasma 
protein binding is low at 15%. Higher levels are achieved in 
females but dosage adjustment is not required in females, 
older individuals or with the use of birth control. The most 
unique feature is the relative terminal long half-life of about 
26 hours, unlike other triptans which range from 3–6 hours. 
Frovatriptan is chieﬂ  y metabolized by CYP1A2 and is cleared 
by the kidney and liver making moderate failure of either 
organ not a limiting factor in treatment. Frovatriptan has a low 
risk of interactions with other drugs (Buchan et al 2002).
Adverse effects of frovatriptan 
(Geraud et al 2002)
Frovatriptin adverse effects are similar to those other trip-
tans. Frovatriptan 2.5 mg compared favorably to sumatriptan Neuropsychiatric Disease and Treatment 2008:4(1) 51
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100 mg with comparative percentages being: dizziness 5.2 
vs 5.8, headache 3.8 vs 4.6; nausea 3.8 vs 7.9; fatigue 3.3 vs 
6.0; paresthesias 2.7 vs 5.4; ﬂ  ushing 2.3 vs 1.0; temperature 
changes sensation 2.1 vs 3.3; abdominal pain 1.9 vs 3.5; dry 
mouth 1.5 vs 2.3; skeletal pain 1.5 vs 3.7; chest pain 1.3 vs 
2.9; somnolence 1.0 vs 2.7; vomiting 0.6 vs 2.5; asthenia 0.4 
vs 2.3; total 36 vs 43. The adverse effects of frovatriptin in 
this study were similar to placebo.
Contraindications to the use 
of frovatriptan
Frovatriptan, like other triptans, should not be used in patients 
with vascular disease including patients with cardiovascular 
disease, peripheral vascular disease, cerebrovascular disease, 
severe renal or hepatic disease, hemiplegic migraine, pregnany, 
lactation, and sensitivity to frovatriptan. Of note is a study of 
frovatriptan used in patients with coronary artery disease or risk 
showing no differences from placebo (Elkind et al 2004).
Principles of frovatriptan use
The principles of use of frovatriptan are the same as with 
other triptans. An accurate diagnosis of migraine must be 
made. Frovatripan should be started as early as possible in 
the migraine attack before the headache becomes moderate or 
severe (Cady et al 2004) and before central sensitization has 
occurred (Malick and Burstein 2000). It should be repeated 
after 2 hours if needed. It should not be used more than 2 
days per week on a consistent basis to prevent medication 
overuse headache. Rescue medication for pain and nausea 
and vomiting should be prescribed to obviate the need for 
emergency room visits. If frovatriptan is not successful in 
acute treatment after a two headache trial, then the addition of 
an anti-inﬂ  ammatory may be helpful. If not, then alternative 
triptans should be considered. Headache frequency should 
be minimized by using preventive medications when the 
frequency is high or the headaches disabling despite acute 
medications. Medication overuse should be avoided and 
detoxiﬁ  cation initiated if needed. A bridging strategy may be 
needed to allow time for the preventive medication to start 
working. Pregnancy plans and issues should be addressed. 
Sleep disorders are very prevalent in migraineurs and may 
need to be addressed. Comorbid conditions often need to be 
treated concurrently with the migraine issues.
Clinical use of frovatriptan
Dose-range-ﬁ  nding studies have established that frovatriptan 
is well tolerated through the dose range of 0.5–40 mg with 
the 2.5 mg dose offering the optimal balance of efﬁ  cacy and 
tolerability for the acute treatment of migraine (Rapoport 
et al 2002).
Three randomized, placebo-controlled, double-blind, 
parallel-group trials performed in 2676 migraineurs. Most 
patients were between age 30 and 50 years, had lifelong 
migraine for 19 years on average, averaged 3 headaches per 
month and one third were triptan naïve. The study established 
a headache response at 2 hours after frovatriptan dosing con-
sistently greater than placebo (p   0.001), about twice as fre-
quently. Headache response at 2 hours ranged from 37%–46% 
for frovatriptan compared to 21%–27% for placebo. At 
4 hours the respective response rates were 56%–65% for 
frovatriptan and 31%–38% for placebo (p   0.001). Time to 
headache response occurred within 1.5 hours in a substan-
tial proportion of patients. Pain-free responses at 2 hours 
were 9%–14% for frovatriptan and 2%–3% for placebo 
(p   0.001). At 4 hours pain-free responses were 27%–32% 
of patients taking frovatriptan and 9%–14% for the placebo 
group (p   0.001). It should be noted that frovatriptan has 
the lowest efﬁ  cacy in 2-hour response, 2-hour pain free 
compared to the other triptans. However, 25% of patients 
taking frovatriptan had headache relief within 1.3–1.7 hours. 
The median time to headache relief was 2.3–3.8 hours for 
frovatriptan compared with 4.4–8.5 hours for placebo. 
Frovatriptan was signiﬁ  cantly superior to placebo in relieving 
nausea, photophobia, and phonophobia. Frovatriptan patients 
returned to normal function signiﬁ  cantly more quickly. Of 
the frovatriptan patients 57%–64% had mild or no functional 
impairment compared with 36% to 43% of the placebo group. 
The median time to meaningful relief was signiﬁ  cantly faster 
for the frovatripan paitent at 6–12 hours compared with 14–17 
hours (p   0.004). The recurrence rate was low in the range 
of 10%–25% and consistently lower than placebo with a 
range of 24%–31% (Ryan et al 2002). The 24 hours sustained 
response (proportion of patients with headache response at 4 
hours and no recurrence in 24 hours) was 47%–51% of the 
frovatriptan patients and 22%–27% of the placebo patients. 
The mean time to recurrence for frovatriptan was 12.1–13.7 
hours compared to 8.2–9.9 hours for the placebo group. 
Frovatriptan satisfaction was rated at 44%–51% compared 
to 17%–30% for placebo.
Thus like other triptans, frovatriptan is successful in pro-
viding reliable and effective treatment of the full spectrum 
of migraine including the associated symptoms of nausea, 
vomiting, photophobia, and phonophobia. In clinical practice 
frovatriptan, like naratriptan, is slower in onset of action than 
the other triptans. However, in the author’s practice about one 
quarter to one third of patients using frovatriptan report a Neuropsychiatric Disease and Treatment 2008:4(1) 52
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speedy onset of action and are satisﬁ  ed with this triptan even 
with migraine attacks with rapid escalation of headache and 
early onset of migraine associated symptoms.
Short- and long-term use of frovatriptan 2.5 mg studies 
established good tolerance by a wide range of subjects with an 
adverse events proﬁ  le similar to that of placebo (Geraud et al 
2002). Like other triptans (Allais et al 2006; Tuchman et al 
2006; Mannix et al 2007a, b) frovatriptan has been shown to 
be effective in the short-term acute treatment of menstrual 
related migraine (MacGregor and Keywood 2000). However, 
a signiﬁ  cant percentage of menstrual-related migraine attacks 
are not as amenable to routine treatment with a triptan. In 
these attacks the migraine may be more severe, longer lasting, 
less responsive to usual treatment and often recurs on repeated 
days during the perimenstrual phase. Options of treatment 
include long term prophylaxis, suppression of ovulation, or 
estrogen supplementation before and during the menstrual 
cycle, and mini-prophylaxis. Mini-prophylaxis with triptans 
in the perimenstrual phase has been reported to be effective 
(Newman et al 1998, 2001; Brandes et al 2007).
A meta-analysis of triptans suggested that headache 
recurrence, often a prominent feature of menstrual migraine, 
appears to be related to both the half-life of the triptan and the 
potency of the triptan agonistic action on the 5HT1B receptor 
(Géraud et al 2003). As outlined above frovatripan possesses 
both of these properties. A randomized, double-blind, placebo-
controlled, three-way crossover study was performed in 546 
women with menstrual related migraine (MRM) (Silberstein 
et al 2004). Patients treated each of three perimenstrual 
periods (PMPs) with placebo, frovatriptan 2.5 mg qd, and 
frovatriptan 2.5 mg bid. The 6-day treatment started 2 days 
before the anticipated start of MRM headache. The primary 
efﬁ  cacy endpoint was incidence of MRM headache during 
the 6-day PMP. Frovatriptan was effective in reducing the 
incidence of menstrually related migraine in both the qd and 
the bid patients with bid being more effective. Both frovat-
riptan regimens also reduced MRM severity (p   0.0001), 
duration (p   0.0001), and the use of rescue medication 
(p   0.01) in a dose-dependent manner. The incidence and 
type of adverse events for both regimens were similar to pla-
cebo and were consistent with those reported for short-term 
migraine management.
The success of frovatriptan in the above study raises the 
possibility of many opportunities for the use of frovatriptan 
in less conventional ways, anecdotally used, but yet to be 
veriﬁ  ed in randomized, double-blind, placebo-controlled 
studies. The author has used frovatriptan with or without an 
anti-inﬂ  ammatory in the following additional situations:
1)  Long-duration migraines, not effectively treated by other 
routine triptans.
2)  Recurrent migraine, occurring after initial success with 
other triptans but recurring the same day or repeatedly 
on the following days.
3) Mini-prophylaxis, to prevent migraines when known 
triggers for an individual which cannot be avoided such 
as plane ﬂ  ights, high altitude trips, or stressful situation 
such as mother-in-law visit.
4) Mini-prophylaxis, to reduce the chance of migraine 
during an important event such as a wedding, business 
meeting, or other important family or social events.
5)  During the prodrome or premonitory phase of migraine 
(Kelman 2004), which can precede the headache and 
associated symptoms by many hours, to reduce or abort 
the subsequent full blown migraine attack.
6)  In cluster headache to provide headache control for up to 
7–10 days often allowing time for deﬁ  nitive preventive 
medication to become active.
Conclusion
Frovatriptan is a well-tolerated triptan, useful in clinical 
practice. It can be used like any other triptan but it has the 
additional unique property of a long half-life of 26 hours 
with a strong 5HT1B receptor agonistic action making it use-
ful for prolonged or recurrent headaches as well as for use 
as in mini-prophylaxis in menstrual migraine and possibly 
other situations.
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